2025-07-13 - Analysis Report
Okay, here's an analysis of TG Therapeutics Inc. (TGTX), incorporating the provided data. I'll present the numerical information first, followed by a concise analysis.

## TG Therapeutics Inc. (TGTX) Analysis

**Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

**1. Performance vs. S&P 500 (VOO):**

*   **TGTX Cumulative Return:** 64.71%
*   **VOO Cumulative Return:** 95.46%
*   **Absolute Deviation:** -28.9%
*   **Relative Deviation:** 15.9 (on a scale where the min/max deviation range is 0-100)
*   **Deviation Range:** Max Deviation: 401.1, Min Deviation: -110.5

**Alpha/Beta Analysis (Selected Years):**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2020-2022  | -76.0% | 70.4% | -78.0% | -0.6  | 1.9    |
| 2021-2023  | -350.0% | 70.4% | -368.0% | -0.8  | 2.7    |
| 2022-2024  | 71.0% | 73.1% | 45.0% | -0.9  | 4.8    |
| 2023-2025  | 72.0% | 73.1% | 24.0% | 0.4  | 5.9    |

**Analysis:**

*   TGTX has underperformed the S&P 500 (VOO) with a cumulative return significantly lower. The relative deviation suggests the underperformance is positioned low within its historical range.
*   The Alpha/Beta analysis reveals fluctuating performance. Recent years (2020-2023) show substantial negative Alpha, indicating underperformance relative to the market. Beta values vary, suggesting different levels of market sensitivity over time. More recent years (2022-2025) show positive Alpha, which may indicate the company is outperforming the market relative to risk.

**2. Recent Stock Price Movement:**

*   **Current Price:** 37.085
*   **Previous Close:** 37.67
*   **Change:** -1.55%
*   **5-Day Moving Average:** 36.853
*   **20-Day Moving Average:** 36.498
*   **60-Day Moving Average:** 37.1203

**Analysis:**

*   The stock price has experienced a slight decrease since the previous close.
*   The 5-day moving average is above the 20-day moving average, potentially indicating a short-term upward trend.  However, the price is slightly below the 60-day moving average.

**3. Technical Indicators:**

*   **Market Risk Indicator (MRI):** 0.3294 (Low Risk)
*   **RSI:** 55.25
*   **PPO:** 0.263
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (5 shares - Safe - MRI:0.33)
*   **Delta_Previous_Relative_Divergence (20-day):** 0.7 (+)
*   **Expected Return:** -245.3%

**Analysis:**

*   The MRI suggests a low-risk market environment for the stock.
*   The RSI is at 55.25, indicating neutral momentum.
*   PPO is at 0.263, which indicates the stock is slightly above its moving average.
*   The positive change in relative divergence over the last 20 days suggests a short-term upward trend relative to the S&P 500.
*   The significant negative expected return suggests concerns about long-term relative performance compared to the S&P 500. The recent price change of -1.55% confirms some downward pressure on the stock, possibly influencing negative expectations.

**4. Recent News & Significant Events:**

*   **[2025-07-10]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-13]:** Analyst discussions about performance, industry trends, and global economic factors.
*   **[2025-07-12]:** Stock volatility influenced by recent news, earnings reports, or executive actions.
*   **[2025-07-11]:** Market experts highlight both risks and opportunities.

**Analysis:**

*   Recent news points to potential volatility and significant events impacting TGTX. Analysts are actively discussing the company, indicating it's under scrutiny. Investors should closely monitor news and company announcements.

**5. Recent Earnings Analysis:**

| 날짜       | EPS   | 매출         |
|------------|-------|--------------|
| 2025-05-09 | 0.03  | 0.12 B$      |
| 2024-11-07 | 0.03  | 0.08 B$      |
| 2024-08-09 | 0.05  | 0.07 B$      |
| 2024-05-06 | -0.07 | 0.06 B$      |
| 2025-05-09 | -0.07 | 0.06 B$      |

**Analysis:**

*   Earnings per share (EPS) has fluctuated, showing both positive and negative values in recent quarters. Recent EPS is $0.03 (B).
*   Revenue has generally trended upward, but is showing at $0.12B.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-03-31 | $0.12B    | 87.14%        |
| 2024-12-31 | $0.11B    | 85.77%        |
| 2024-09-30 | $0.08B    | 88.86%        |
| 2024-06-30 | $0.07B    | 88.70%        |
| 2024-03-31 | $0.06B    | 91.43%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2025-03-31 | $0.24B    | 2.13%     |
| 2024-12-31 | $0.22B    | 10.49%    |
| 2024-09-30 | $0.19B    | 2.02%     |
| 2024-06-30 | $0.18B    | 3.87%     |
| 2024-03-31 | $0.16B    | -6.69%    |

**Analysis:**

*   Revenue has been generally increasing.
*   Profit margins are consistently high.
*   Equity has been increasing.
*   ROE (Return on Equity) has been fluctuating.

**7. Overall Summary:**

TGTX has underperformed the S&P 500 over the period examined.  While recent revenue and profit margins are positive, the negative expected return raises concerns about long-term relative performance. Recent news suggests potential volatility and significant events impacting the company. The stock is showing mixed signals with the MRI in low-risk, and positive recent (20 day) delta_previous relative divergence. While revenue and profit margins appear strong, ROE has been volatile. Investors should carefully consider the risks and opportunities and closely monitor news and company announcements.
